Completed PHASE2 INTERVENTIONAL NCT00220129

Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus

Neoadjuvant Epirubicin, Cisplatin and Capecitabine (Xeloda) [ECX] Followed by Definitive Chemoradiation With or Without Surgery for Patients With Newly Diagnosed Localized Squamous Cell Carcinoma of the Oesophagus

Sponsor: Royal Marsden NHS Foundation Trust

Conditions Oesophageal Carcinoma

Interventions Epirubicin, Cisplatin, Capecitabine Surgical Resection

Updated 5 times since 2017 Last updated: Dec 15, 2009 Started: Nov 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Oesophageal Carcinoma, this trial is completed. The trial is conducted by Royal Marsden NHS Foundation Trust and has accumulated 5 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Royal Marsden NHS Foundation Trust

Data source: Royal Marsden NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sutton, United Kingdom